Organic Walnuts Are Linked to a Dangerous E. Coli Outbreak
At least a dozen people in California and Washington have been sickened with E. coli food poisoning linked to organic walnuts sold in bulk in 19 states, U.S. health officials said Tuesday. The nuts were sold in natural food and co-op stores such as Whole Foods and Market of Choice. Seven people have been hospitalized and two have developed a dangerous kidney disease known as hemolytic uremic syndrome, officials with the Centers for Disease Control and Prevention said. Gibson Farms Inc. of Hollister, California, has recalled potentially affected walnuts with expiration dates between May 21, 2025 an...
Source: TIME: Health - May 1, 2024 Category: Consumer Health News Authors: Jonel Aleccia/AP Tags: Uncategorized healthscienceclimate wire Source Type: news

E. coli outbreak at Calgary daycare centres is over, Alberta Health Services says
The E. coli outbreak left 38 kids and one adult hospitalized. Doctors diagnosed 23 patients with severe illness or hemolytic uremic syndrome while eight received peritoneal dialysis. (Source: CBC | Health)
Source: CBC | Health - November 1, 2023 Category: Consumer Health News Tags: News/Canada/Calgary Source Type: news

FDA accepts application for Roche ’s crovalimab for the treatment of PNH, a rare life-threatening blood condition
Acceptance based on the phase III COMMODORE 2 study, which demonstrated crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal haemoglobinuria (PNH)1If approved, crovalimab will be the first monthly subcutaneous treatment for PNH, with the option to self-administer outside of a supervised healthcare settingFiling applications have also been accepted in the EU, China and Japan, andsubmissions to other regulatory authorities around the world are ongoingBasel, 6 September 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accep...
Source: Roche Investor Update - September 6, 2023 Category: Pharmaceuticals Source Type: news

New data show Roche ’s subcutaneously administered crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal haemoglobinuria (PNH)
The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with comparable safety, in people new to C5 inhibitors1Monthly self-administration of subcutaneous crovalimab has the potential to address the high burden of a disease that requires lifelong treatment including in settings where access to currentC5 inhibitors is limited1,2The COMMODORE 1 study in people switching from currently approved C5 inhibitors supported the consistent benefit-risk profile of crovalimab as seen in the COMMODORE 2 study3Basel, 09 June 2023 - Roche (SIX: RO, ROG; ...
Source: Roche Investor Update - June 9, 2023 Category: Pharmaceuticals Source Type: news

New data show Roche ’s subcutaneously administered crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal haemoglobinuria (PNH)
The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with comparable safety, in people new to C5 inhibitors1Monthly self-administration of subcutaneous crovalimab has the potential to address the high burden of a disease that requires lifelong treatment including in settings where access to currentC5 inhibitors is limited1,2The COMMODORE 1 study in people switching from currently approved C5 inhibitors supported the consistent benefit-risk profile of crovalimab as seen in the COMMODORE 2 study3Basel, 09 June 2023 - Roche (SIX: RO, ROG; ...
Source: Roche Media News - June 9, 2023 Category: Pharmaceuticals Source Type: news

Roche announces positive data from global phase III programme for crovalimab in PNH, a rare life-threatening blood condition
The COMMODORE 2 study met its co-primary efficacy endpoints, showingcrovalimab achieved disease control in people with paroxysmal nocturnalhaemoglobinuria (PNH) who have not been previously treated with complement inhibitorsThe results of the phase III COMMODORE 1 study in people with PNH switching from currently approved C5 inhibitors, supported thefavourable benefit-risk profile ofcrovalimab, as seen in the pivotal COMMODORE 2 studyResults from both studies will be submitted to regulatory authorities around the world and presented at an upcoming medical meetingBasel, 7 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) t...
Source: Roche Media News - February 7, 2023 Category: Pharmaceuticals Source Type: news

Roche announces positive data from global phase III programme for crovalimab in PNH, a rare life-threatening blood condition
The COMMODORE 2 study met its co-primary efficacy endpoints, showingcrovalimab achieved disease control in people with paroxysmal nocturnalhaemoglobinuria (PNH) who have not been previously treated with complement inhibitorsThe results of the phase III COMMODORE 1 study in people with PNH switching from currently approved C5 inhibitors, supported thefavourable benefit-risk profile ofcrovalimab, as seen in the pivotal COMMODORE 2 studyResults from both studies will be submitted to regulatory authorities around the world and presented at an upcoming medical meetingBasel, 7 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) t...
Source: Roche Investor Update - February 7, 2023 Category: Pharmaceuticals Source Type: news

Roche ’s subcutaneous crovalimab given every four weeks achieves disease control in people with PNH, a life-threatening blood condition
The phase III COMMODORE 3 study ofcrovalimab met primary endpoints of transfusion avoidance andhaemolysis control in people with paroxysmal nocturnal hemoglobinuria (PNH)1COMMODORE 3 is the first China-specific study in PNH. Current treatment options are extremely limited in China, resulting in significant levels of disease-related morbidity and mortality for people living with PNH2Based on these datacrovalimab has received Breakthrough Therapy Designation and is under Priority Review for approval in ChinaBasel, 11 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive new data from the phase III COMMO...
Source: Roche Media News - December 11, 2022 Category: Pharmaceuticals Source Type: news

Roche ’s subcutaneous crovalimab given every four weeks achieves disease control in people with PNH, a life-threatening blood condition
The phase III COMMODORE 3 study ofcrovalimab met primary endpoints of transfusion avoidance andhaemolysis control in people with paroxysmal nocturnal hemoglobinuria (PNH)1COMMODORE 3 is the first China-specific study in PNH. Current treatment options are extremely limited in China, resulting in significant levels of disease-related morbidity and mortality for people living with PNH2Based on these datacrovalimab has received Breakthrough Therapy Designation and is under Priority Review for approval in ChinaBasel, 11 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive new data from the phase III COMMO...
Source: Roche Investor Update - December 11, 2022 Category: Pharmaceuticals Source Type: news

Health Officials Say Romaine Lettuce is Safe to Eat Again as Nationwide E. Coli Outbreak has Ended
The US Centers for Disease Control and the US Food and Drug Administration have declared that the recent nationwide E. Coli outbreak, which contaminated romaine lettuce, ended as of Wednesday. Authorities traced the outbreak back to the Salinas Valley growing region in California. The FDA has lifted a consumer advisory to avoid romaine lettuce from Salinas “as the growing season for this region is over and there is no longer a need for consumers to avoid it.” Health officials had previously advised consumers, retailers and restaurants to throw out any romaine lettuce grown in the Salinas, Calif. region. People...
Source: TIME: Health - January 16, 2020 Category: Consumer Health News Authors: Sanya Mansoor Tags: Uncategorized onetime public health Source Type: news

It ’ s OK To Eat Romaine Lettuce Again
(CNN) — Caesar salad lovers rejoice — your crispy romaine lettuce leaves are OK to eat now. The nationwide, monthslong E. coli outbreak linked to romaine lettuce ended Wednesday, according to the US Centers for Disease Control and Prevention and the US Food and Drug Administration. The romaine, which came from Salinas, California, infected a total of 167 people in 27 states. This included 85 hospitalizations, including 15 patients who developed a type of kidney failure — hemolytic uremic syndrome — known to be associated with this particular type of bacteria, E. coli O157:H7. The toxin produced by t...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 16, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Syndicated CBSN Boston CNN Romaine Lettuce Source Type: news

Benefits of early eculizumab in haemolytic uraemic syndrome
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 31, 2019 Category: Drugs & Pharmacology Source Type: news

CDC Says 102 People Infected With E. coli After Eating Romaine Lettuce Sourced From One Region
The Centers For Disease Control and Prevention (CDC) advises consumers, retailers and restaurants throw out any romaine lettuce that was grown in the Salinas, Calif. region. The number of E. coli infections has increased to 102 cases reported in 23 states, including 10 cases of kidney failure, since the outbreak was declared late November. E. coli illnesses began in late September, according to the CDC, which is continuing to investigate if any other products can be linked to the outbreak. No common grower, supplier, distributor or brand of lettuce has been identified, the CDC reports. At least one case involves a child un...
Source: TIME: Health - November 27, 2019 Category: Consumer Health News Authors: Jasmine Aguilera Tags: Uncategorized public health Source Type: news

CDC Says 67 People Infected With E. coli After Eating Romaine Lettuce Sourced From One Region
Ahead of the Thanksgiving holiday, the Centers For Disease Control and Prevention (CDC) advises consumers, retailers and restaurants throw out any romaine lettuce that was grown in the Salinas, Calif. region after 67 cases of E. coli have been reported in 19 states, including six cases of kidney failure. E. coli illnesses began in late September, according to the CDC, which is continuing to investigate if any other products can be linked to the outbreak. At least one case involves a 3-year-old child, and multiple cases involve children under 18 years old, CDC spokesperson Laura Whitlock tells TIME. “If it’s ro...
Source: TIME: Health - November 27, 2019 Category: Consumer Health News Authors: Jasmine Aguilera Tags: Uncategorized public health Source Type: news

FDA Clears Ravulizumab for Atypical Hemolytic Uremic Syndrome FDA Clears Ravulizumab for Atypical Hemolytic Uremic Syndrome
At 26 weeks, complete thrombotic microangiopathy (TMA) response was achieved in 54% of adults and 71% of children treated with the long-acting C5 complement inhibitor.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 21, 2019 Category: Neurology Tags: Nephrology News Alert Source Type: news